The US FDA has approved a new drug that would boost the global fight against multi-drug resistant bacteria. The new beta-lactamase inhibitor, Avibactam, is being combined with the popular cephalosporin, Ceftazidime, and the combination will be marketed as Avycaz (ceftazidime-avibactam).
The new drug is indicated for treatment of complicated intra-abdominal infections in combination with metronidazole, and complicated urinary tract infections, including kidney infections (pyelonephritis), who have limited or no alternative treatment options.
According to MedEnhanz, the other beta-lactamase inhibitors are clavulanic acid (used in combination with Amoxicillin as Augmentin or Ticarcillin as Timentin); sulbactam (used in combination with Ampicillin as Unasyn); and tazobactam (used in combination with piperacillin as Zosyn or Tazocin).
Some of the common bacteria capable of producing beta-lactases include Staphlococcus, Klebsiella pneumoniae, Enterobacteriaceae, Morganella spp, Haemophilus influenza, and Neisseria gonorrhea amongst others.